rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

TransMedics Group, Inc.

TMDX · Nasdaq

Health CareMedical DevicesNot moving yet

TMDX stood above a rising 150-day average in 18 of the last 52 weekly readings, and has been out of that trend for the last 32 weeks. It is 15.5% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−7 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 32
Industry in uptrend
27% -7 in 4 wk
Insider buys, 12 months
$1.2M
Insider sales, 12 months
$7.9M
Officials’ trades on record
3
Institutions holding
352 (-31)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 18 of 52 weeks.

20 Apr – 19 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$4.5M$0$1.7MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

3 disclosed lines: House 0, Senate 0, executive 3; 1 people.

WhoDidAmountTraded
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$1k–$15k29 Jul 2026filed 22 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$15k–$50k8 Jul 2026filed 22 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$1k–$15k15 May 2026filed 1 Jul 2026

Insiders

Buy orders, 12 months2
Sale orders, 12 months11
Buyers · sellers2 · 7
WhoDidSharesTraded
David WeillDirectorbought1,336at $81.6311 Sep 2026filed 14 Sep 2026
Thomas J. GundersonDirectorsold9,624at $75.0615 Jun 2026filed 17 Jun 2026
Gerardo HernandezChief Financial Officersold1,324at $147.214 Mar 2026filed 4 Mar 2026
Gerardo HernandezChief Financial Officersold5,912at $147.214 Mar 2026filed 4 Mar 2026
David WeillDirectorsold3,571at $146.824 Mar 2026filed 6 Mar 2026
Stephanie LovellDirectorsold1,193at $149.624 Mar 2026filed 6 Mar 2026
Nicholas CorcoranSee remarkssold2,966at $139.122 Mar 2026filed 4 Mar 2026
Anil P. RanganathSee remarkssold864at $139.122 Mar 2026filed 4 Mar 2026
Gerardo HernandezChief Financial Officersold375at $139.122 Mar 2026filed 4 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders352-31 on the quarter
New · exited71 · 102
Reported value$2.3B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20265,596,549$371.7M+303,218+5.7%
FMR LLCadded · filed 13 Aug 20265,133,328$341.0M+37,085+0.7%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 20261,933,989$128.5M+14,454+0.8%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20261,497,600$99.5M+19,448+1.3%
STATE STREET CORPadded · filed 7 Aug 20261,420,421$94.3M+100,942+7.7%
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.added · filed 14 Aug 2026910,495$60.5M+24,654+2.8%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026894,913$59.5M+55,758+6.6%
Hood River Capital Management LLCadded · filed 14 Aug 2026751,133$49.9M+51,363+7.3%
DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 2026610,107$40.5M+93,428+18.1%
BRAIDWELL LPadded · filed 14 Aug 2026609,715$40.5M+280,324+85.1%
31 Mar 2023 – 30 Jun 2026
192292392Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

David Weill Company insiderDirector · last 11 Sep 20263 · 7
James R. Tobin Company insiderDirector · last 17 Aug 20260 · 10
Donald J. Trump Executive branchWhite House Office · last 29 Jul 20260 · 3
Gerardo Hernandez Company insiderChief Financial Officer · last 10 Jul 20260 · 3
Nicholas Corcoran Company insiderSee remarks · last 10 Jul 20260 · 3
Waleed H. Hassanein Company insiderPresident & CEO · last 10 Jul 20263 · 41
Thomas J. Gunderson Company insiderDirector · last 15 Jun 20260 · 1
Edward M. Basile Company insiderDirector · last 20 May 20261 · 11
Edwin Kania Company insiderDirector · last 20 May 20262 · 0
Merilee Raines Company insiderDirector · last 20 May 20260 · 0
Stephanie Lovell Company insiderDirector · last 20 May 20260 · 3
Matthew S. Forsyth Company insiderOfficer · last 19 May 20260 · 0

Same industry

RCEL Avita MedicalLeading+100%
HAE HaemoneticsLeading+48%
ATRC AtriCureLeading+47%
HTFL HeartflowLeading+47%

Distance from each stock’s own 150-day average.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202559.9%
Operating profit marginFY 2025 · to 31 Dec 202517.9%
Free cash flow marginFY 2025 · to 31 Dec 202522.1%
Return on capital employedFY 2025 · to 31 Dec 202511.1%
Cash conversionFY 2025 · to 31 Dec 2025101%
Debt to equityFY 2025 · to 31 Dec 20250.02×
Research spendFY 2025 · to 31 Dec 202511.4%
Share count trendFY 2025 · to 30 Jan 20260.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$488.9M
Free cash flowFY 2025 · to 31 Dec 2025$133.6M

Analyst forecasts

No analyst forecasts yet.